Controversies in renal cell carcinoma: Treatment choice after progression on vascular endothelial growth factor-targeted therapy

European Journal of Cancer

Volumn 50, Issue 7, 2014, Pages 1321-1329

  Calvo, Emiliano ^a   Grünwald, Viktor ^b   Bellmunt, Joaquim ^c  

^a Hospital Madrid Norte Sanchinarro   (Spain)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Quality of life; Renal cell carcinoma; Second line; Sequencing; Treatment planning

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERFERON; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

QUALITY OF LIFE; RENAL CELL CARCINOMA; SECOND-LINE; SEQUENCING; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897431648     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.02.007     Document Type: Review

References (56)

1. R.J. Motzer, T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, and S. Oudard et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
2. C.N. Sternberg, I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, and J. Wagstaff et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
3. B.I. Rini, S. Halabi, J.E. Rosenberg, W.M. Stadler, D.A. Vaena, and S.S. Ou et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
4. B. Ljungberg, N.C. Cowan, D.C. Hanbury, M. Hora, M.A. Kuczyk, and A.S. Merseburger et al. EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
5. B. Escudier, T. Eisen, C. Porta, J.J. Patard, V. Khoo, and F. Algaba et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl. 7 2012 vii65 vii71
6. R.J. Motzer, T.E. Hutson, D. Cella, J. Reeves, R. Hawkins, and J. Guo et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722 731
7. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, and A. Kapoor et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
8. A. Levy, J. Menard, L. Albiges, Y. Loriot, M. Di Palma, and K. Fizazi et al. Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients Eur J Cancer 49 2013 1898 1904
9. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
10. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
11. B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, and T.E. Hutson et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
12. R.J. Motzer, B. Escudier, P. Tomczak, T.E. Hutson, M.D. Michaelson, and S. Negrier et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 14 2013 552 562
13. M.R. Harrison, D.J. George, M.S. Walker, C. Chen, B. Korytowsky, and D.T. Kirkendall et al. "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy Clin Genitourin Cancer 11 2013 441 450
14. M.R. Matrana, C. Duran, A. Shetty, L. Xiao, B.J. Atkinson, and P. Corn et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies Eur J Cancer 49 2013 3169 3175
15. J. Rautiola, T. Utriainen, K. Peltola, H. Joensuu, and P. Bono Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma Acta Oncol 53 2014 113 118
16. J.D. Hainsworth, M.S. Rubin, E.R. Arrowsmith, J. Khatcheressian, E.J. Crane, and L.A. Franco Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: A Sarah Cannon Oncology Research Consortium Phase II trial Clin Genitourin Cancer 11 2013 270 275
17. K. Park, J.L. Lee, I. Park, S. Park, Y. Ahn, and J.H. Ahn et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI Med Oncol 29 2012 3291 3297
18. N. Calvani, F. Morelli, S. Leo, L. Orlando, L. Lombardi, and A. Gnoni et al. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol 29 2012 1908 1913
19. C. Porta, G. Procopio, G. Carteni, R. Sabbatini, A. Bearz, and I. Chiappino et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 2011 E250 E257
20. G. Di Lorenzo, G. Carteni, R. Autorino, G. Bruni, M. Tudini, and M. Rizzo et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 2009 4469 4474
21. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
22. J. Busch, C. Seidel, C. Kempkensteffen, M. Johannsen, I. Wolff, and S. Hinz et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors Eur Urol 60 2011 1163 1170
23. J.A. Garcia, T.E. Hutson, P. Elson, C.L. Cowey, T. Gilligan, and C. Nemec et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 2010 5383 5390
24. L. Bergmann, P.J. Goebell, U. Kube, M. Kindler, E. Herrmann, and J. Janssen et al. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study Onkologie 36 2013 95 100
25. C.C. Chen, G.P. Hess, Z. Liu, D.H. Gesme, S.S. Agarwala, and C.C. Garay et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma Clin Genitourin Cancer 10 2012 256 261
26. Iacovelli R, Carteni G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur J Cancer 2013;49:2134-42.
27. Hutson T, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman K, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after suninitib in patients with metastatic renal cell carcinoma. J Clin Oncol 2013 Dec 2. [Epub before print].
28. E. Calvo, B. Escudier, R.J. Motzer, S. Oudard, T.E. Hutson, and C. Porta et al. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study Eur J Cancer 48 2012 333 339
29. D. Cella Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes Cancer Treat Rev 35 2009 733 737
30. K. Gupta, J.D. Miller, J.Z. Li, M.W. Russell, and C. Charbonneau Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review Cancer Treat Rev 34 2008 193 205
31. L.I. Wagner, L. Wenzel, E. Shaw, and D. Cella Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions J Clin Oncol 25 2007 5058 5062
32. B.J. Escudier, C. Porta, P. Bono, U. De Giorgi, O. Parikh, and R.E. Hawkins et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) - PISCES study, NCT 01064310 J Clin Oncol 30 June 20 Supplement 2012 CRA4502
33. D. Cella, B. Escudier, B. Rini, C. Chen, H. Bhattacharyya, and J. Tarazi et al. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial Br J Cancer 108 2013 1571 1578
34. D. Cella, B. Escudier, B. Rini, C. Chen, H. Bhattacharyya, and J. Tarazi et al. Time to deterioration (TTD) in patient-reported outcomes in phase 3 AXIS trial of axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) Eur J Cancer 47 Suppl. 1 2011 Abstract 3006
35. B.I. Rini, M. Garrett, B. Poland, J.P. Dutcher, O. Rixe, and G. Wilding et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis J Clin Pharmacol 53 2013 491 504
36. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Siebels et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
37. M.Y. Al-Marrawi, B.I. Rini, L.C. Harshman, G. Bjarnason, L. Wood, and U. Vaishampayan et al. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients Target Oncol 8 2013 203 209
38. K. Zimmermann, A. Schmittel, U. Steiner, A.M. Asemissen, M. Knoedler, and E. Thiel et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib Oncology 76 2009 350 354
39. I. Tamaskar, J.A. Garcia, P. Elson, L. Wood, T. Mekhail, and R. Dreicer et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy J Urol 179 2008 81 86
40. F. Azam, S. Mehta, and A.L. Harris Mechanisms of resistance to antiangiogenesis therapy Eur J Cancer 46 2010 1323 1332
41. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
42. B.I. Rini New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance Clin Cancer Res 16 2010 1348 1354
43. A. Blesius, B. Beuselinck, C. Chevreau, A. Ravaud, F. Rolland, and S. Oudard et al. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial Clin Genitourin Cancer 11 2013 128 133
44. G. Di Lorenzo, C. Buonerba, P. Federico, P. Rescigno, M. Milella, and C. Ortega et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma Eur Urol 58 2010 906 911
45. V. Grunwald, C. Seidel, M. Fenner, A. Ganser, J. Busch, and S. Weikert Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies Br J Cancer 105 2011 1635 1639
46. Motzer R, Szczylik C, Vogelzang NJ, Sternberg CN, Porta C, Zolnierek J, et al. Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway-targeted and 1 prior mTOR inhibitor therapy. European Congress of, Cancer 2013:Abstract LBA-34.
47. R. Motzer, C. Barrios, T. Kim, S. Falcon, T. Cosgriff, and W. Harker et al. RECORD-3: phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma J Clin Oncol 31 2013 Abstract 4504
48. R. Danesi, J.P. Boni, and A. Ravaud Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications Cancer Treat Rev 39 2013 784 792
49. J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, and K. Hazell et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 2008 1603 1610
50. A. O'Donnell, S. Faivre, H.A. Burris 3rd, D. Rea, V. Papadimitrakopoulou, and N. Shand et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 2008 1588 1595
51. E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman, and J. Boni et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol 22 2004 2336 2347
52. M. Hidalgo, J.C. Buckner, C. Erlichman, M.S. Pollack, J.P. Boni, and G. Dukart et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer Clin Cancer Res 12 2006 5755 5763
53. C. Tanaka, T. O'Reilly, J.M. Kovarik, N. Shand, K. Hazell, and I. Judson et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data J Clin Oncol 26 2008 1596 1602
54. M.B. Atkins, M. Hidalgo, W.M. Stadler, T.F. Logan, J.P. Dutcher, and G.R. Hudes et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
55. N.J. Vogelzang, M. Bhor, Z. Liu, R. Dhanda, and T.E. Hutson Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network Clin Genitourin Cancer 11 2013 115 120
56. Pfizer Inc., Axitinib (AG-013736) for the treatment of patients with advanced renal cell carcinoma. FDA Oncologic Drugs Advisory Committee Briefing Document (NDA 202324), 2011.